| ［1］ |
Furst DE, Keystone EC, Braun J, et al. Updated consensus state⁃ment on biological agents for the treatment of rheumatic diseases, 2010［J］. Ann Rheum Dis, 2011,70（Suppl 1）:i2⁃36. doi: 10.1136/ard.2010.146852.<br />
|
| ［2］ |
Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF⁃blockade therapy: a review and analysis of 127 cases［J］. J Dermatolog Treat, 2009,20（2）:100⁃108. doi: 10.1080/09546630802441234.<br />
|
| ［3］ |
Harrison MJ, Dixon WG, Watson KD, et al. Rates of new⁃onset psoriasis in patients with rheumatoid arthritis receiving anti⁃tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register［J］. Ann Rheum Dis, 2009,68（2）:209⁃215. doi: 10.1136/ard.2007.087288.<br />
|
| ［4］ |
Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis［J］. Semin Arthritis Rheum, 2010,40（3）:233⁃240. doi: 10.1016/j.semarthrit.2010.04.003.<br />
|
| ［5］ |
Buisson A, Cuny JF, Barbaud A, et al. Methotrexate for psoriasi⁃form lesions associated with anti⁃tumour necrosis factor therapy in inflammatory bowel disease［J］. Aliment Pharmacol Ther, 2012,35（10）:1175⁃1180. doi: 10.1111/j.1365⁃2036.2012.05082.x.<br />
|
